ArticleCellular and molecular life sciences : CMLS2026
Inhibition of connexin hemichannels protects retinal ganglion cells against ocular nerve injury.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Retinal ganglion cell (RGC) degeneration caused by optic nerve injury and diseases such as glaucoma leads to irreversible vision loss, yet effective neuroprotective treatments remain elusive. Secondary degeneration driven by astrocytic gliosis and neuroinflammation contributes substantially to neuronal death. Connexin 43 (Cx43), a gap junction protein abundantly expressed in astrocytes, is a key mediator of these secondary responses. Using an optic nerve crush (ONC) mouse model that recapitulates traumatic optic neuropathy, we found that Cx43 haploinsufficiency significantly preserved visual function, limited inner retina thinning, and protected RGCs from apoptosis and macrophage infiltration. Mechanistically, cytokine stimulation of astrocytes triggered Cx43 hemichannel opening and the release of inflammatory ATP and neurotoxic glutamate, which in turn promote RGC apoptosis. A novel Cx43(M1) antibody selectively inhibited astrocytic hemichannels, prevented the release of these factors, and reduced RGC death. Remarkably, a single administration of Cx43(M1) 30 min after ONC improved visual function and RGC survival for at least four weeks, accompanied by attenuated gliosis and reduced Cx43 expression. Together, these findings identify astrocytic Cx43 hemichannels as key mediators of secondary RGC neurodegeneration and demonstrate that their targeted inhibition confers sustained neuroprotection following optic nerve injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.